Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Anacor Pharmaceuticals Inc (NASDAQ: ANAC) acted responsibly on behalf of investors’ profitability in the planned $5.2 billion sale to Pfizer Inc (NYSE: PFE).

On May 16, 2016, Anacor Pharmaceuticals Inc (NASDAQ: ANAC) and Pfizer Inc (NYSE: PFE) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Pfizer will offer Anacor shareholders $99.25 per share in cash for all outstanding shares.    

Based in Palo Alto, CA, and founded in 2000 Anacor Pharmaceuticals Inc is a biopharmaceutical company, focusing on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

The investigation is looking to uncover whether Anacor Pharmaceuticals Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $130.00 per share.

If you purchased Anacor Pharmaceuticals Inc (NASDAQ: ANAC) prior to May 16, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185